Usana Health Sciences Shares Fall on Lowered Outlook, 3Q Revenue Decline
Dow Jones2026/11/03 23:56By Elias Schisgall
Shares of Usana Health Sciences fell after the company lowered its outlook and reported lower revenue in the third quarter.
Shares were down 10% to $13.34 after-hours on Tuesday. The stock closed up 1.2% at $14.87 and had fallen 24% this year through the close.
The multilevel marketer of nutritional and personal-care products on Tuesday said it now expects full-year consolidated net sales of nearly $900 million, down from its earlier guidance for $910 million.
Usana guided for adjusted earnings of 55 cents a share, down from its previous view of 76 cents.
The company reported a loss of $5.6 million, or 30 cents a share, in the quarter ended Oct. 3. That compares with a loss of $6.5 million, or 36 cents a share, a year earlier.
Stripping out certain one-time items, the company reported an adjusted loss of 11 cents a share.
Revenue fell to $205.9 million from $213.7 million a year earlier.
"As we continue our transformation to an omnichannel health and wellness company, our third-quarter results were mixed, with meaningful improvement in some areas and results that fell short of our expectations in others," Chief Executive Kevin Guest said. "We are investing across each of our businesses to strengthen their long-term competitive position and made clear progress in key areas."
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
November 03, 2026 18:56 ET (23:56 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
